Invesco Exchange-Traded Fund Trust II has filed its latest NPORT-P report, providing crucial insights into its asset management performance as of August 31, 2026. The report reveals that the fund holds total assets exceeding $302 million, with net assets reported at approximately $248 million. This filing is significant as it underscores Invesco's ongoing commitment to transparency and regulatory compliance in the investment sector.
Invesco Exchange-Traded Fund Trust II, identified by the Central Index Key (CIK) 0001378872, is classified under the investment entity type. The firm has undergone several name changes in the past, previously known as PowerShares Exchange-Traded Fund Trust II. The latest filing, dated October 30, 2026, follows a series of NPORT-P submissions made on the same day, indicating an active reporting period.
According to the filing, the total liabilities of the fund stand at approximately $54 million. This results in a net asset value of around $248 million, reflecting a solid financial position for the fund. The report also highlights the fund's engagement with various financial institutions as borrowers, including notable names like J.P. Morgan Securities LLC and Citigroup Global Markets Inc., among others.
The filing indicates that the fund's investments are primarily in equity securities, with no reported unrealized gains or losses in various categories, including commodities and credit contracts. The report shows a commitment to maintaining a diversified portfolio, with significant allocations to various corporate entities.
This update is particularly relevant for investors and analysts monitoring the exchange-traded fund (ETF) sector, which continues to grow in popularity. Invesco's proactive reporting and management strategies may influence competitive dynamics within the industry, particularly among other investment firms focused on ETFs.
Looking ahead, the filing does not specify what actions will follow this report. However, stakeholders will likely keep a close eye on future filings to assess the fund's performance and strategic direction in an evolving market landscape.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






